Related Experiment Video

Updated: Feb 28, 2026

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

m5C: Novel Diagnostic and Drug Repurposing Targets for Nonalcoholic Steatohepatitis

Shuxian Chen¹, Renquan Duan², Jingyi Qiu¹

¹Department of Gastroenterology, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang, China, hbmu.edu.cn.

International Journal of Genomics

|February 27, 2026

Abstract

Background:

Epigenetic medication, such as RNA 5-methylcytosine (m5C), is well-recognized as a key regulator in hepatic metabolism and immune responses. However, m5C regulatory mechanisms in NASH pathogenesis have not yet been clearly elucidated.

Methods:

By utilizing three bulk profiles of NASH patients acquired from GEO and integrative bioinformatic pipelines, such as Limma framework, consensus clustering, and machine learning, we first identified m5C-related molecular subgroups and hub genes for NASH patients. Besides, diagnostic performance and biological characteristics of m5C-related hub gene were estimated at bulk level. Indeed, the heterogeneity of m5C-related hub gene for NASH patients was deciphered in single-cell transcriptomic profiles at temporal and spatial manners, especially in artificial intelligence (AI)-driven virtual cells. Furthermore, potential therapeutic agents targeting m5C-associated hub genes for the treatment of NASH were enriched by AI-driven drug enrichment framework (DrugReflector) based on NASH bulk profile and then validated by molecular docking. Finally, in vitro studies quantified the expression of m5C-associated hub genes compared to normal control.

Results:

m5C can divide NASH patients into two various consensus groups with different molecular and immune patterns. Furthermore, ERCC2 and FOXC2 can be considered two upregulated m5C-associated hub genes involved in NASH pathogenesis, which were mainly distributed at cholangiocyte. BRD-K93672499 can be considered a multitarget therapeutic strategy targeting ERCC2 and FOXC2 for the treatment of NASH.

Conclusion:

Our study first deciphered the m5C in predictive and therapeutic potential for NASH patients, which gains more insight into their personalized and precision medicine.

Keywords:

drug repurposing m5C machine learning multiomics nonalcoholic steatohepatitis

More Related Videos

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery

Published on: May 19, 2018

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

Ultrasound II: Endoscopic Ultrasound and FibroScan

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):

Targets for Drug Action: Overview

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

Articles linked to this work by shared authors, journal, and citation graph.

A Synergistic Triphase Electrolyte Design Enables 4.6 V LiCoO2 Quasi-Solid-State Batteries with Ultra-Long Cycling.

Advanced materials (Deerfield Beach, Fla.)·2026

Quantifying the Correlation Between Capacity Utilization and Electrolyte Dosage for Ultrahigh-Energy-Density 769 Wh Kg-1 Rechargeable Lithium Metal Batteries.

Advanced materials (Deerfield Beach, Fla.)·2026

Sulfur vacancy engineering enables a synergistic multisite platform for dual-functional sensing of benzimidazole fungicides.

Journal of hazardous materials·2026

All-trans retinoic acid suppresses systemic inflammation induced by severe fever with thrombocytopenia syndrome virus in mice.

Nature microbiology·2026

A retrospective study of differential prognostic factors in early-onset versus late-onset colorectal cancer: a comprehensive clinical and machine learning analysis.

PeerJ·2026

CsFDL1-CsFTL3 Complex Represses CsFTL3 via Negative Feedback to Fine-Tune Flowering in Chrysanthemum seticuspe.

Plant, cell & environment·2026

See all related articles